Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C

International Journal of Obesity

Volumn 33, Issue 11, 2009, Pages 1309-1317

  Hsieh, M H ^a   Ho, C K ^b   Hou, N J ^a,b   Hsieh, M Y ^b   Lin, W Y ^a,b   Yang, J F ^b   Chiu, C C ^b   Huang, J F ^a,b   Chang, N C ^b   Wang, C L ^a,b   Dai, C Y ^b,c   Chuang, W L ^b,c   Yu, M L ^b,c  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ALT; AST; BMI; GGT; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; LIPID STORAGE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STEATOSIS; TAIWAN; BLOOD; ENZYMOLOGY; HEPATITIS B; LIVER DISEASES; MIDDLE AGED; OBESITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; TAIWAN; YOUNG ADULT;

EID: 70450265247     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.172     Document Type: Article

References (40)

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
3. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabetes 2002; 51: 3120-3127.
4. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care 2000; 23: 1242-1248.
5. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
6. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399-404.
7. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-414.
8. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-1077
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
10. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83 (9B): 25F-29F.
11. Unwin N. The metabolic syndrome. J R Soc Med 2006; 99: 457-462.
12. Miyatake N, Matsumoto S, Makino H, Numata T. Comparison of hepatic enzymes between Japanese men with and without metabolic syndrome. Acta Med Okayama 2007; 61: 31-34. (Pubitemid 46423113)
13. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28: 2913-2918.
14. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005; 28: 1757-1762.
15. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 2118-2123.
16. Tsai CH, Li TC, Lin CC. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J 2008; 101: 900-905.
17. Lai SW, Liao KF, Li TC, Lin HF, Lin WY, Lin CH. Metabolic syndrome in older people in Taiwan: a hospital-based study. Intern Med J 2006; 36: 648-651.
18. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006; 105: 626-635.
19. [Revised Diagnostic Criteria of Metabolic Syndrome for adults aged more or equal 20 years old in Taiwan, 2006]. In: Bureau of Health Promotion. Department of Health: Taipei, ROC (Taiwan).
20. Jia WP, Xiang KS, Chen L, Lu JX, Wu YM. Epidemiological study on obesity and its comorbidities in urban Chinese older than 20 years of age in Shanghai, China. Obes Rev 2002; 3: 157-165.
21. Gill TP. Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolic point of view: abdominal obesity. Asia Pac J Clin Nutr 2001; 10: 85-89.
22. Alberti KG, Zimmet P, Shaw J. The metabolic syndromeFa new worldwide definition. Lancet 2005; 366: 1059-1062. (Pubitemid 41338752)
23. Chang CJ, Wu CH, Chang CS, Yao WJ, Yang YC, Wu JS et al. Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. Int J Obes Relat Metab Disord 2003; 27: 253-259.
24. Saito T, Misawa K, Kawata S. 1. Fatty liver and non-alcoholic steatohepatitis. Intern Med 2007; 46: 101-103.
25. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006; 22: 437-443.
26. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 705-709.
27. Kawai N, Kawai T, Kawai K. Ultrasonic and laboratory studies on fatty liver in white-collar workers. Nippon Shokakibyo Gakkai Zasshi 1995; 92: 1058-1065.
28. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a 'bright' liver echo pattern. Ital J Gastroenterol Hepatol 1997; 29: 351-356.
29. Ionescu DL. Microvesicular steatosis. Rev Med Chir Soc Med Nat Iasi 2002; 107: 268-272.
30. De Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R, Gonzalez Hernandez JM. Influence of insulin resistance in obese patients on elevated serum alanine aminotransferase. Eur Rev Med Pharmacol Sci 2007; 11: 21-25.
31. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47: 1363-1370.
32. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-962.
33. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
34. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
35. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610-1614.
36. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-767.
37. Michelle Lai BH. Role of liver biopsy in patients with normal ALT and high HBV DNA. Hepatology 2005; 42 (Suppl 1): 720A.
38. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-964.
39. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983.
40. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003; 55: 77-85